PMID- 26428031
OWN - NLM
STAT- MEDLINE
DCOM- 20160218
LR  - 20221207
IS  - 1941-9260 (Electronic)
IS  - 0032-5481 (Linking)
VI  - 127
IP  - 8
DP  - 2015
TI  - Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 
      2 diabetes therapy.
PG  - 827-41
LID - 10.1080/00325481.2015.1096743 [doi]
AB  - In type 2 diabetes mellitus (T2DM), decreased pancreatic beta-cell function and 
      increased insulin resistance contribute to a steady decline in glucose 
      homeostasis. Maintaining levels of glycated hemoglobin </=7.0% is thought to reduce 
      the microvascular and possibly macrovascular complications that result if T2DM is 
      not properly managed. Recent guidelines have recognized the importance of 
      postprandial glucose (PPG) control in reducing cardiovascular risks, and have 
      recommended a more patient-centered approach. Glucagon-like peptide-1 receptor 
      agonists (GLP-1 RAs) mimic the action of the endogenous gastrointestinal hormone 
      GLP-1 to activate the insulin response in pancreatic beta cells in a 
      glucose-dependent manner. Prandial GLP-1 RAs have a short plasma half-life and 
      are particularly effective at targeting PPG elevations, whereas long-acting 
      non-prandial GLP-1 RAs are more effective at reducing fasting plasma glucose. 
      These differences highlight the potential for treatment with these agents to be 
      tailored to the need of individual patients and their glycemic imbalance. All 
      GLP-1 RAs are being evaluated in long-term cardiovascular outcome trials. To 
      date, the only cardiovascular trial that has been completed is the ELIXA trial 
      for lixisenatide, which was found to meet the pre-specified criterion of 
      non-inferiority versus placebo in terms of cardiovascular outcomes.
FAU - Davidson, Jaime A
AU  - Davidson JA
AD  - a Touchstone Diabetes Center, The University of Texas, Southwestern Medical 
      Center , Dallas, TX, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151001
PL  - England
TA  - Postgrad Med
JT  - Postgraduate medicine
JID - 0401147
RN  - 0 (Blood Glucose)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Delayed-Action Preparations
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Gastric Emptying/drug effects
MH  - Glucagon/metabolism
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glycated Hemoglobin/drug effects
MH  - Half-Life
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse 
      effects/pharmacokinetics/*therapeutic use
MH  - Postprandial Period/*physiology
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - GLP-1 receptor agonist
OT  - Type 2 diabetes
OT  - drug efficacy
OT  - drug safety
EDAT- 2015/10/03 06:00
MHDA- 2016/02/19 06:00
CRDT- 2015/10/03 06:00
PHST- 2015/10/03 06:00 [entrez]
PHST- 2015/10/03 06:00 [pubmed]
PHST- 2016/02/19 06:00 [medline]
AID - 10.1080/00325481.2015.1096743 [doi]
PST - ppublish
SO  - Postgrad Med. 2015;127(8):827-41. doi: 10.1080/00325481.2015.1096743. Epub 2015 
      Oct 1.